ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2250

A Clinical Analysis of Adult Patients with Autoimmune- and Infection-Associated Hemophagocytic Lymphohistiocytosis

Min W. So1, Bon S. Koo1, You J. Kim1, Yong-G Kim1, Wook J. Seo2, Chang-K Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adult-onset Still's disease, phagocytosis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially life-threatening disease. Secondary HLH is associated with various clinical conditions, including infections, malignancies, and autoimmune diseases. Although many previous studies reviewed the clinical features, treatments, and outcomes of autoimmune- or infection-associated HLH, respectively, only a few studies have evaluated the differences between autoimmune- and infection-associated HLH to these factors. The purpose of our study was to identify and compare the clinical features, treatments, and outcomes of patients with secondary HLH caused by diseases other than malignancy at a single institution.

Methods: We retrospectively collected data on 33 adult patients who were diagnosed with autoimmune- or infection-associated HLH from 1997 to 2011 at a single tertiary hospital. Patients were eligible if they were over 15 years of age and met five criteria for HLH. Patients were classified as having autoimmune- or infection-associated HLH and the medical data on each patient were reviewed.

Results: Twelve patients were diagnosed as having autoimmune-associated HLH. Among the 12 patients, nine patients had SLE and three patients had adult-onset still’s disease. Steroid therapy was given to all patients. Eleven patients recovered from autoimmune associated HLH. Twenty one patients were diagnosed as having infection-associated HLH. The most common infection associated with HLH was EBV (n = 19, 90.5%) followed by hepatitis A virus (n = 1, 4.8%) and parvovirus B19 (n = 1, 4.8%). Thirteen patients were treated according to the HLH protocol. Among the 21 patients, five patients underwent allogenic HCT. Only four patients survived without disease; three of the five transplant recipients and one of the 16 patients who had received no transplants. With respect to clinical characteristics, splenomegaly was more common in patients with infection-associated HLH (p = 0.010). With respect to laboratory characteristics, the platelet count and the level of ESR were lower in the infection-associated HLH group (p = 0.009 and p = 0.020). Hyperbilirubinemia was more prominent in the infection-associated HLH group (p = 0.015). Concerning treatment, patients with infection-associated HLH received the more commonly administered cyclosporine A and etoposide therapy than patients with autoimmune-associated HLH. Patients with infection-associated HLH (19.0%) had a lower survival rate than patients with autoimmune-associated HLH (91.7%).

Conclusion: Secondary HLH is a syndrome-based diagnosis as it encompasses various heterogeneous conditions. In the present study, autoimmune-associated HLH has mild disease activity and is included mild disease entity. Although there is still considerable debate regarding the ideal initial management approach for patients with autoimmune-associated HLH, corticosteroid administration alone seems to be sufficient. In secondary HLH, an exhaustive search for an underlying cause, such as infection or autoimmune disease, is warranted as the results of such research may guide treatment regimens and help predict outcomes.


Disclosure:

M. W. So,
None;

B. S. Koo,
None;

Y. J. Kim,
None;

Y. G. Kim,
None;

W. J. Seo,
None;

C. K. Lee,
None;

B. Yoo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-clinical-analysis-of-adult-patients-with-autoimmune-and-infection-associated-hemophagocytic-lymphohistiocytosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology